Thilaganathan B, Nicolaides K H, Morgan G
Harris Birthright Research Centre for Fetal Medicine, King's College Hospital School of Medicine, London.
Br J Haematol. 1994 Jul;87(3):634-6. doi: 10.1111/j.1365-2141.1994.tb08328.x.
Flow cytometry was used to determine the percentage and number of circulating CD34+ cells in fetal blood from 100 pregnancies at 13-38 weeks gestation. When expressed as a percentage of the total number of lymphocytes, the proportion of CD34+ cells decreased exponentially from a mean of 11.1% (9.2 x 10(7)/l) at 13 weeks to 1.0% (3.0 x 10(7)/l) at 38 weeks (r = 0.751, P < 0.0001). The use of primitive fetal blood CD34+ progenitor cells for prenatal somatic gene therapy may have distinct advantages over postnatal somatic gene therapy.
采用流式细胞术测定了100例孕13 - 38周胎儿血中循环CD34 +细胞的百分比和数量。以淋巴细胞总数的百分比表示时,CD34 +细胞比例呈指数下降,从孕13周时的平均11.1%(9.2×10⁷ /升)降至孕38周时的1.0%(3.0×10⁷ /升)(r = 0.751,P < 0.0001)。与出生后体细胞基因治疗相比,使用原始胎儿血CD34 +祖细胞进行产前体细胞基因治疗可能具有明显优势。